Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Immunophenotypic and detailed cytogenetic characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia

ABSTRACT: Affymetrix SNP arrays were performed according to the manufacturer's directions on DNA extracted from cultured cells. Five cell lines (MOLM-13, SKM-1, F-36P, SKK-1 and OHN-GM) derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia have been studied by flow cytometry, conventional cytogenetics and whole genome single nucleotide polymorphism microarrays, in order to deeply characterize.

ORGANISM(S): Homo sapiens

PROVIDER: GSE80314 | GEO | 2017/01/01

SECONDARY ACCESSION(S): PRJNA318533

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Affymetrix SNP array data for myelodysplastic syndrome with 5q deletion treated with lenalidomide

Project description:Lenalidome is a drug especially effective in low risk myelodysplastic syndromes (MDS) with isolated 5q deletion. However, 25% of the patients did not respond. TP53 mutations have been described to play a role in the disease progression, and karyotypic complexity also has an important impact in the outcome. We selected 53 MDS patients with 5q deletion and treated with lenalidomide and we studied by the following techniques: conventional G-banding cytogenetics (CC), single nucleotide polymorphism arrays (SNP-A) and sequencing, in order to assess their impact on treatment response and disease progression. Low karyotypic complexity (by CC), a high baseline platelet count (>280x103/L) and TP53 unmutated gene status are associated with the achievement of hematological response (P=0.005, P=0.008 and P=0.057, respectively). In a multivariate model, the most important predictors for lenalidomide failure are karyotypic complexity (P=0.014) and a platelet count below 280x103/L (P=0.042). Additionally, none of the TP53 mutated cases achieved complete cytogenetics response. Nevertheless, inclusion of defects by SNP-A did not allow for a better separation of responders and non responders. These findings constitute a useful reference data to be considered before lenalidomide treatment enrollment. Affymetrix SNP arrays were performed according to the manufacturer's directions on DNA extracted from bone marrow or peripheral blood and, in some cases, also lymphocytes CD3 isolated from peripheral blood samples. Copy number analyses of Affymetrix 250K and 6.0 SNP arrays were performed for 53 MDS with 5q deletion samples. There are also 30 samples from lymphocytes CD3 isolated from peripheral blood, which were used as germ-line DNA (control).

2013-07-01 | E-GEOD-35656 | biostudies-arrayexpress

Cytogenetic features in myelodysplastic syndromes.

Project description: Not available

| S-EPMC2413090 | biostudies-other

Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders.

Project description: Not available

| S-EPMC5841340 | biostudies-literature

Affymetrix SNP array data for HNSCC samples

Project description:Affymetrix SNP arrays were performed according to the manufacturer's directions on DNA extracted from cryopreserved HNSCC samples.

2016-03-29 | GSE74555 | GEO

Genomic aberrations in metaplastic breast carcinomas and adenomyoepitheliomas

Project description:Affymetrix Oncoscan arrays were performed according to the manufacturer's directions on DNA extracted from FFPE-breast cancer tissues.

2019-04-23 | GSE107394 | GEO

Oncoscan for subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid-papillary carcinoma

Project description:Affymetrix Oncoscan arrays were performed according to the manufacturer's directions on DNA extracted from FFPE-breast cancer tissues.

2017-02-09 | GSE94695 | GEO

Oncoscan for HER2 copy number assessment

Project description:Affymetrix Oncoscan arrays were performed according to the manufacturer's directions on DNA extracted from FFPE-breast cancer tissues.

2016-07-01 | GSE83916 | GEO

Affymetrix SNP array data for 4 MYC-negative B-cell lymphoma cases and 2 B-cell lymphoma cell lines (SU-DHL-5 and HT)

Project description:Affymetrix SNP arrays were performed according to the manufacturer's directions on DNA extracted from blood samples and cell lines

2014-01-10 | GSE47507 | GEO

Affymetrix OncoScan FFPE Array array data from Li-Fraumeni Syndrome tumors

Project description:Loss of heterzygosity in TP53 Affymetrix OncoScan FFPE arrays were performed according to the manufacturer's directions on DNA extracted from tumors

2015-02-03 | GSE64293 | GEO

CN profiles of microglandular adenosis and adjacent breast cancer

Project description:CN profiles of microglandular adenosis and adjacent breast cancer Affymetrix Oncoscan arrays were performed according to the manufacturer's directions on DNA extracted from FFPE-breast tumor tissues.

2021-01-01 | GSE141831 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data